LARIMAR THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $14.00K.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $30.00K, a 25.00% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $11.00K.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $24.00K.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $77.00K, a 133.33% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $33.00K.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2014 was $3.00K.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2012 was $13.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $14.00K 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $77.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | $30.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $11.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $33.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $24.00K 10-Q · filed 2024-10-30 | |
| 2014-12-31 | $3.00K 10-K · filed 2017-03-10 | |
| 2012-12-31 | $13.00K 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |